Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Related Topics:
Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
A sign for the Food And Drug Administration outside its headquarters in Maryland. Photo: Getty Images
China technology

Are clinical trials about to become a new front in the US-China biotech race?

China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned.

Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

videocam
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Clara Chan Ka-chai, CEO of Hong Kong Investment Corporation (HKIC) Photo: Enoch Yiu
Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

China economy

Outside In | China’s export success is a by-product of self-reliance

But while the export surge is an accidental consequence of self-sufficiency and competitive manufacturers, the solution is not protectionism.

videocam
7
Advertisement
Advertisement
Advertisement
Science

China biotech sector fears policy backlash after girl dies in gene-editing trial

Scientist says child’s death reveals ‘serious failures in risk assessment, transparency and institutional oversight’.

videocam
Scientists in the biotech sector fear China will impose restrictive regulations after a child died in a gene-editing trial in 2025. Photo: Shutterstock
US-China trade war

Record Chinese biotech out-licensing meets rising US scrutiny

Surging cross-border deals out of China are running headlong into intensifying US national security fears.

videocam
22
Banking & finance

As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec

Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.

China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

videocam
In addition to surging novel drug development, China’s cross-border deals with global giants show no sign of abating. Photo: Shutterstock
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

Hong Kong’s skyline is seen from The Peak on June 1. Photo: Karma Lo
China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
26
US-China relations

US National Science Foundation to ban projects with flagged Chinese institutions

Raising security fears, NSF moves from case-by-case approval to full ban on working with restricted entities and their employees.

China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

Chinese biotech and innovative drug firms are rapidly closing the gap with its US rivals as it continues to develop RAS-targeted cancer therapies. Photo: Shutterstock
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

Royalty Pharma is scouting the Asia-Pacific region for innovative biotechnology start-ups with late-stage pharmaceutical pipelines. Photo: Shutterstock
China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Medicine

China closing in but US leads in biotech quality and commercial reach: survey

The Cure survey said China leads ⁠in clinical development and supply chain, and rated US funding cuts a bigger threat than China competition.

videocam
Advertisement
Advertisement
Advertisement
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Chinese pharmaceutical companies may expand into international markets in the coming years. Photo: Shutterstock
US-China trade war

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

videocam
13
Chinese biotech companies have risen up the value chain in recent years, with cross-border licensing deals worth a record US$60 billion in the first quarter of 2026, according to the National Medical Products Administration. Photo: Getty Images
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

US-China relations

Opinion | How US tech hegemony is locking out the Global South

The world deserves better than a monopoly that builds walls and hobbles development.

videocam
4
China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

Hong Kong’s Tuen Mun Hospital has for the first time in the city used a non-invasive ultrasound procedure to treat a Parkinson’s disease patient with uncontrollable tremors. Photo: Handout
China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Illustration by Henry Wong
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement